ARID1A and urinary bladder carcinoma: ARID1A‐mutated bladder cancer cells exhibit sensitivity to PI3K inhibitors; thus combining EZH2 inhibitors with PI3K inhibitors can yield a synergistic anti‐tumour effect, consequently, ARID1A mutated bladder cancer may be treated with EZH2 and/or PI3K inhibitors [60].